CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 106 enrolled
Drug / intervention
Teriflunomidedrug
Likely dose
Teriflunomide 14mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02490982
NCT02490982N/ACompleted
CompareCT.gov

Teriflunomide Observational Effectiveness Study

Centre hospitalier de l'Université de Montréal (CHUM)·observational·Posted Jul 7, 2015·Updated Aug 18, 2021

In Brief

An observational study evaluating Teriflunomide for Relapsing Remitting Multiple Sclerosis. Completed, enrolled 106 participants across 1 site.

Detailed Summary

The main goal of this investigator-initiated study is to evaluate the effectiveness and efficacy of Teriflunomide in a population of Relapsing Remitting Multiple Sclerosis (RRMS) patients treated in regular practice, over a period of at least two years, in the regular setting of a Multiple Sclerosis Clinic.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsing Remitting Multiple Sclerosis
CountriesCanada
CollaboratorsGenzyme, a Sanofi Company, Montreal Neurological Institute and Hospital

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 7, 2015
Enrollment StartNov 1, 2015
Primary CompletionDec 1, 2018
Study CompletionJun 28, 2021
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 11.0 years ago

Interventions

Teriflunomidedrug

The prescription of Teriflunomide administered orally as a 14mg daily compound to RRMS patients.